Financial Performance - The company's revenue for Q3 2021 was ¥259,627,467.85, representing a 26.65% increase year-over-year, while the year-to-date revenue reached ¥717,454,934.17, up 19.65% compared to the same period last year [3] - The net profit attributable to shareholders was a loss of ¥1,268,883.99 for Q3 2021, a 97.38% increase in loss compared to the same period last year, with a year-to-date loss of ¥5,387,497.77, reflecting a 95.65% increase in loss [3] - The basic and diluted earnings per share for Q3 2021 were both -¥0.0056, indicating a 97.59% increase in loss per share year-over-year [3] - The total operating revenue for the third quarter was CNY 717,454,934.17, an increase of 19.7% compared to CNY 599,609,116.26 in the same period last year [22] - The net profit for the period was CNY 6,638,870.37, a significant recovery from a net loss of CNY 123,176,402.66 in the previous year [23] - The company reported a gross profit margin of approximately 1.0% for the quarter, compared to a negative margin in the same quarter last year [23] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥76,981,749.49, showing a significant increase of 1,133.70% compared to the previous year [3] - The net cash flow from operating activities for Q3 2021 was ¥76,981,749.49, a significant improvement compared to a net outflow of ¥7,447,173.00 in Q3 2020 [27] - Total cash inflow from operating activities reached ¥804,665,843.06, while cash outflow was ¥727,684,093.57, resulting in a net increase in cash flow [27] - Cash flow from investment activities showed a net outflow of ¥8,241,753.26, compared to a smaller outflow of ¥4,543,129.61 in the same period last year [27] - The net cash flow from financing activities was negative at ¥108,492,628.30, indicating a decrease in cash from financing compared to a positive flow of ¥62,500,740.44 in Q3 2020 [28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,640,618,686.10, down 8.88% from the end of the previous year [3] - The total assets decreased to CNY 1,640,618,686.10 from CNY 1,800,518,724.44, a decline of 8.9% [20] - The total liabilities decreased to CNY 814,855,621.02 from CNY 927,906,148.41, a reduction of 12.2% [20] - The company’s total equity decreased to CNY 825,763,065.08 from CNY 872,612,576.03, a decline of 5.4% [20] - The total liabilities of the company as of the end of Q3 2021 were ¥1,800,518,724.44, indicating a stable financial position [31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,255 [12] - The top 10 shareholders hold a total of 56,000,000 shares, with the largest shareholder, Weng Zhangguo, owning 6.92% (15,772,409 shares) [12] - The total number of restricted shares held by major shareholders remains unchanged at 15,676,966 shares, with no new restrictions imposed during the reporting period [15] Research and Development - The company experienced a 136.39% increase in development expenditures, amounting to ¥7,967,700, attributed to capitalized R&D investments [7] - Research and development expenses were CNY 41,276,842.49, slightly down from CNY 41,926,381.74 in the previous year [23] - The company has not disclosed any new product or technology developments during this reporting period [13] Inventory and Receivables - The company reported a 69.33% increase in receivables financing, totaling ¥5,625,300, primarily due to increased use of bank acceptance bills for settling payments [7] - Accounts receivable decreased from 197,477,573.70 yuan at the end of 2020 to 157,044,385.70 yuan, a reduction of about 20.5% [18] - The company reported a decrease in inventory from 122,439,751.31 yuan at the end of 2020 to 128,793,329.47 yuan, indicating a slight increase of about 5.5% [18] Borrowings and Financing - The company’s long-term borrowings decreased by 65% to ¥37,300,000, as a result of reclassifying long-term bank loans to current liabilities [7] - The company’s cash inflow from financing activities included ¥62,000,000.00 from borrowings, highlighting reliance on debt financing [28] - The company’s cash outflow for repaying debts was ¥114,260,000.00, which reflects its commitment to managing liabilities [28] Audit and Compliance - The report for the third quarter of 2021 was not audited [33] - The company has not applied the new leasing standards retrospectively for prior comparative data [33]
仟源医药(300254) - 2021 Q3 - 季度财报